JP2003524018A5 - - Google Patents

Download PDF

Info

Publication number
JP2003524018A5
JP2003524018A5 JP2001562581A JP2001562581A JP2003524018A5 JP 2003524018 A5 JP2003524018 A5 JP 2003524018A5 JP 2001562581 A JP2001562581 A JP 2001562581A JP 2001562581 A JP2001562581 A JP 2001562581A JP 2003524018 A5 JP2003524018 A5 JP 2003524018A5
Authority
JP
Japan
Prior art keywords
antibody
conjugate
domain
angiogenesis
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2001562581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003524018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/002062 external-priority patent/WO2001062800A1/en
Publication of JP2003524018A publication Critical patent/JP2003524018A/ja
Publication of JP2003524018A5 publication Critical patent/JP2003524018A5/ja
Abandoned legal-status Critical Current

Links

JP2001562581A 2000-02-24 2001-02-23 フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 Abandoned JP2003524018A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51208200A 2000-02-24 2000-02-24
US09/512,082 2000-02-24
PCT/EP2001/002062 WO2001062800A1 (en) 2000-02-24 2001-02-23 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Publications (2)

Publication Number Publication Date
JP2003524018A JP2003524018A (ja) 2003-08-12
JP2003524018A5 true JP2003524018A5 (cg-RX-API-DMAC10.html) 2008-04-17

Family

ID=24037588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001562581A Abandoned JP2003524018A (ja) 2000-02-24 2001-02-23 フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用

Country Status (6)

Country Link
US (1) US8097254B2 (cg-RX-API-DMAC10.html)
EP (1) EP1259548A1 (cg-RX-API-DMAC10.html)
JP (1) JP2003524018A (cg-RX-API-DMAC10.html)
AU (2) AU4243201A (cg-RX-API-DMAC10.html)
CA (1) CA2400622A1 (cg-RX-API-DMAC10.html)
WO (1) WO2001062800A1 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
PL369371A1 (en) 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
SI1817345T1 (sl) * 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
DE502005009389D1 (de) 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
DK2721152T3 (da) 2011-06-15 2019-07-01 Navigo Proteins Gmbh Dimere bindingsproteiner baseret på modificerede ubiquitiner
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US11230576B2 (en) 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
IL310865A (en) 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
EP3689903A4 (en) * 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. BINDING OF PROTEIN TO FIBRONECTIN B DOMAIN
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
TWI844524B (zh) 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
KR20210104106A (ko) 2018-12-18 2021-08-24 나피고 프로타인스 게엠베하 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
WO2021016091A1 (en) 2019-07-19 2021-01-28 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
WO2021116337A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
ES2987329T3 (es) 2020-05-22 2024-11-14 Philogen Spa Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales
US20250161475A1 (en) 2022-03-21 2025-05-22 Philogen S.P.A Tnfalpha immunoconjugate preparation
MX2024011514A (es) 2022-03-23 2024-09-24 Philogen Spa Preparacion de un inmunoconjugado de il2.
EP4558519A1 (en) 2022-07-22 2025-05-28 Philogen S.p.A. Anti-cd28 antibodies
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
CN115505040A (zh) * 2022-08-01 2022-12-23 江苏艾洛特医药研究院有限公司 一种用于检测edb蛋白的免疫组化试剂盒及其应用
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
CN118108796B (zh) * 2024-04-08 2024-12-24 中国科学院近代物理研究所 靶向治疗脑胶质瘤的211At标记多肽及其制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0460709B1 (en) 1985-01-28 1997-05-21 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
WO1989006283A1 (en) 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5177015A (en) * 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH0276598A (ja) 1988-09-14 1990-03-15 Fujita Gakuen 抗ed−b抗体
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
CA2065299C (en) * 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5120830A (en) * 1990-10-25 1992-06-09 Washington University Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen
JPH04169195A (ja) 1990-10-31 1992-06-17 Fujita Gakuen 抗ed―bモノクローナル抗体
US5140470A (en) * 1991-01-07 1992-08-18 New Focus, Inc. Optical mounting apparatus
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5561114A (en) * 1992-09-25 1996-10-01 Otsuka Pharmaceutical Factory Inc. Adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5348485A (en) * 1993-04-12 1994-09-20 Electronic Retailing Systems Int'l Inc. Electronic price display system with vertical rail
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) * 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
ITFI940095A1 (it) 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
CA2165228A1 (en) 1994-12-27 1996-06-28 Yoshitoshi Itaya Metal chelate forming peptides and use thereof
WO1996023816A1 (en) 1995-02-01 1996-08-08 British Technology Group Limited Radiolabelled proteins
US5796535A (en) * 1995-05-12 1998-08-18 Cirrus Logic, Inc. Sampled amplitude read channel employing a user data frequency synthesizer and a servo data frequency synthesizer
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) * 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) * 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
CA2326821C (en) 1998-04-02 2010-09-28 The Board Of Regents Of The University Of Oklahoma Nucleic acid encoding hyaluronan synthase and methods of use
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US5997842A (en) * 1998-04-13 1999-12-07 Light Sciences Limited Partnership Radionuclide excited phosphorescent material for administering PDT
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
DE19947559A1 (de) 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
EP1130099A1 (en) 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
WO2001096599A2 (en) 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
US20020197700A1 (en) 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
US6693245B2 (en) * 2000-09-29 2004-02-17 Anritsu Corporation Electronic balance which is easily assembled, maintained, downsized and improved with respect to weighing performance, and method for manufacturing the same
WO2002069907A2 (en) * 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
PL369371A1 (en) 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
AR040956A1 (es) * 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
JP4169195B2 (ja) 2003-06-24 2008-10-22 株式会社河合楽器製作所 電子楽音発生装置の記録制御装置
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs

Similar Documents

Publication Publication Date Title
JP2002514405A5 (cg-RX-API-DMAC10.html)
JP7722990B2 (ja) アミロイド沈着物を標的化するための修飾免疫グロブリン
CA2333833A1 (en) Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis
AU2011298369B2 (en) Peptide or peptide complex binding to 2 integrin and methods and uses involving the same
AU2003243651B2 (en) Specificity grafting of a murine antibody onto a human framework
CN101981053B (zh) 聚乙二醇化的AβFAB
ES2440652T3 (es) Anticuerpos humanizados anti-MAG y sus usos para el tratamiento de apoplejía
JP5221641B2 (ja) 腫瘍転移の血管新生と関連するフィブロネクチンのed−a抗原
JP2017503511A5 (cg-RX-API-DMAC10.html)
US5811522A (en) Recombinant humanized anti-FB5 antibodies
JP2007228979A (ja) 癌マーカー用生物合成結合蛋白質
JP2009149686A (ja) フィブリンのd二量体断片に特異的なdd−3b6/22から誘導されるヒト化抗体
JP2009514540A (ja) 機能−阻止抗−ed−b−フィブロネクチン抗体(private)の同定及び特徴化
RU2004130428A (ru) Избирательный направленный перенос в сосудистую сеть опухоли с использованием молекул антител
JP2004135675A (ja) 哺乳動物ケモカイン
JP2003516934A (ja) ヒト骨髄前駆細胞阻害性因子−1(mpif−1)を用いる、細胞、組織および器官の損傷を処置または予防する方法
JP6605331B2 (ja) 抗体−薬物複合体治療での使用のための免疫造影剤
KR20230042301A (ko) 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
JP2026513849A (ja) Pdgfrアルファを発現するがんを画像診断するための試薬及び方法
JP2016515093A (ja) 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤
EA048681B1 (ru) Модифицированные иммуноглобулины для нацеливания на амилоидные отложения
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios